Research programme: adult pluripotent stem cell therapies for cancer - APstem Therapeutics
Latest Information Update: 02 Sep 2023
At a glance
- Originator APstem Therapeutics
- Class Antineoplastics; Pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 May 2023 Early research in Cancer in USA (Parenteral) (APstem-Therapeutics pipeline, May 2023)